StockData
Celularity Inc logo

Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30
$0.57−0.05 (-7.75%)

Close on Nov 17, 2026Market cap $18.53MP/E –Yield –

Celularity operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Celularity's operating income for the twelve months ending Jun 30, 2026 was -$49.33M. For fiscal 2025 it was -$61.31M. The highest annual figure on record is -$1.68M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$61.31M–
FY2024Dec 31, 2024-$38.36M–
FY2023Dec 31, 2023-$192.29M–
FY2022Dec 31, 2022-$25.60M–
FY2021Dec 31, 2021-$109.06M–
FY2020Dec 31, 2020-$151.93M–
FY2019Dec 31, 2019-$1.68M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.24M–
Q1 FY2026Mar 31, 2026-$10.13M–
Q4 FY2025Dec 31, 2025-$22.06M–
Q3 FY2025Sep 30, 2025-$12.90M–
Q2 FY2025Jun 30, 2025-$15.86M–
Q1 FY2025Mar 31, 2025-$10.49M–
Q4 FY2024Dec 31, 2024-$9.28M-169.7%
Q3 FY2024Sep 30, 2024-$11.53M–
Q2 FY2024Jun 30, 2024-$10.18M–
Q1 FY2024Mar 31, 2024-$7.38M–
Q4 FY2023Dec 31, 2023$13.32M-23.8%
Q3 FY2023Sep 30, 2023-$99.26M–
Q2 FY2023Jun 30, 2023-$42.48M-1117.4%
Q1 FY2023Mar 31, 2023-$63.87M–
Q4 FY2022Dec 31, 2022$17.49M–
Q3 FY2022Sep 30, 2022-$5.65M-151.8%
Q2 FY2022Jun 30, 2022$4.18M–
Q1 FY2022Mar 31, 2022-$41.61M–
Q4 FY2021Dec 31, 2021-$14.95M-235.2%
Q3 FY2021Sep 30, 2021$10.90M–
Q2 FY2021Jun 30, 2021-$60.61M–
Q1 FY2021Mar 31, 2021-$44.40M–
Q4 FY2020Dec 31, 2020$11.06M–
Q3 FY2020Sep 30, 2020-$4.81M–
Q2 FY2020Jun 30, 2020-$208.23K–
Q1 FY2020Mar 31, 2020-$241.64K–
Q4 FY2019Dec 31, 2019-$1.37M–
Q3 FY2019Sep 30, 2019-$202.00K–
Q2 FY2019Jun 30, 2019-$115.25K–
Q1 FY2019Mar 31, 2019-$121–

More Celularity figures

See a number that looks wrong?